Editorial: Why the randomized controlled trial is still at the apex and the gold standard for evaluating new medical and surgical interventions

Aleksi Reito; Søren Overgaard

doi:10.2340/17453674.2025.44947

Editorial: Why the randomized controlled trial is still at the apex and the gold standard for evaluating new medical and surgical interventions

Ortopædkirurgisk Afdeling M

Originalsprog	Engelsk
Tidsskrift	Acta orthopaedica
Vol/bind	96
Sider (fra-til)	873-874
Antal sider	2
ISSN	1745-3674
DOI	https://doi.org/10.2340/17453674.2025.44947
Status	Udgivet - 25 nov. 2025

Adgang til dokumentet

10.2340/17453674.2025.44947Licens: CC BY

Citationsformater

@article{4b3c6c8ea24b4334b5e676231e779068,

title = "Editorial: Why the randomized controlled trial is still at the apex and the gold standard for evaluating new medical and surgical interventions",

author = "Aleksi Reito and S{\o}ren Overgaard",

year = "2025",

month = nov,

day = "25",

doi = "10.2340/17453674.2025.44947",

language = "English",

volume = "96",

pages = "873--874",

journal = "Acta orthopaedica",

issn = "1745-3674",

publisher = "Medical Journals Sweden AB",

}

TY - JOUR

T1 - Editorial

T2 - Why the randomized controlled trial is still at the apex and the gold standard for evaluating new medical and surgical interventions

AU - Reito, Aleksi

AU - Overgaard, Søren

PY - 2025/11/25

Y1 - 2025/11/25

U2 - 10.2340/17453674.2025.44947

DO - 10.2340/17453674.2025.44947

M3 - Editorial

C2 - 41287576

SN - 1745-3674

VL - 96

SP - 873

EP - 874

JO - Acta orthopaedica

JF - Acta orthopaedica

ER -